Reversal of neuromuscular block
British Journal of Anaesthesia, ISSN: 0007-0912, Vol: 103, Issue: 1, Page: 115-129
2009
- 145Citations
- 204Captures
- 3Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations145
- Citation Indexes145
- 145
- CrossRef103
- Captures204
- Readers204
- 204
- Mentions3
- References2
- Wikipedia2
- News Mentions1
- News1
Most Recent News
A Study of Residual Curarization Incidence in China
STUDY INFORMATION OFFICIAL TITLE: A Perspective, Multicentre, Randomized,Blind Study of Residual Curarization Incidence in China CURRENT STATUS: Unknown status STUDY TYPE: Interventional SPONSOR AGENCY:Peking University
Review Description
The use of anticholinesterases to reverse residual neuromuscular block is efficacious only if recovery is already established. It was originally advised that at least the second twitch (T2) of the train-of-four response should be detectable before neostigmine is administered. Even in these circumstances, the full effect of anticholinesterases takes up to 10 min to achieve. Anticholinesterases also have muscarinic side-effects that require an antimuscarinic to be administered concomitantly. An ideal reversal agent could be given at any time after the administration of a neuromuscular blocking agent (NMBA), and should have no muscarinic side-effects. The gamma cyclodextrin, sugammadex, has been demonstrated to effectively antagonize even profound block produced by the aminosteroid NMBAs, rocuronium and vecuronium, by chelating them. The complex is then excreted in the urine. Sugammadex is ineffective in antagonizing the benzylisoquinolinium NMBAs. The dose should be adjusted according to the degree of residual block: sugammadex 16 mg kg −1 for immediate reversal; 4–8 mg kg −1 for antagonizing profound block (post-tetanic count 1–2); and 2 mg kg −1 to antagonize moderate block (when T2 is detectable). As yet, the extent of any side-effects that may occur with this new antagonist is not fully known, although rarely adverse cardiovascular effects (hypotension, hypertension, prolonged QT interval) have already been reported.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0007091217340485; http://dx.doi.org/10.1093/bja/aep093; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=67650713727&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/19468024; https://linkinghub.elsevier.com/retrieve/pii/S0007091217340485; https://dx.doi.org/10.1093/bja/aep093
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know